Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY
For the quarter, the company's revenue from operations rose 11% year-on-year (YoY) to ₹875 crore, compared to ₹790 crore in Q1 FY25. Reported revenue, including other income, stood at ₹892 crore, up 10% YoY.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) came in at ₹224 crore, growing 19% from ₹188 crore last year. The EBITDA margin improved to 25% from 23% YoY, driven by revenue growth and cost optimization.
Net profit (PAT) surged 59% to ₹87 crore from ₹54 crore in the same quarter last year. The PAT margin expanded to 10% from 7% YoY. Key Financials: YoY comparison Metric Q1 FY25 Q1 FY26 YoY Change (%) Revenue from operations (₹ Cr) 790 875 ↑ 11% Reported revenue (₹ Cr) 808 892 ↑ 10% EBITDA (₹ Cr) 188 224 ↑ 19% EBITDA margin (%) 23 25 ↑ 200 bps Net profit (PAT) (₹ Cr) 54 87 ↑ 59% PAT margin (%) 7 10 ↑ 300 bps
Commenting on the results, Peter Bains, Managing Director and CEO, highlighted that the performance was in line with expectations, supported by continued conversion of pilot programs into longer-term contracts in the Research Services business and progress in the Biologics manufacturing division.
Deepak Jain, CFO, noted that the quarter's profitability also benefitted from a tax credit, and the company maintained a strong balance sheet to invest in capabilities and technology.
Other business highlights included the successful completion of USFDA inspections, inauguration of a state-of-the-art peptide laboratory, and recognition by TIME and Statista as one of the world's most sustainable companies.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
4 hours ago
- Time Magazine
Trump Says He 'Probably' Won't Run For President Again
President Donald Trump said he would 'probably' not run for president again after his second term in an interview with CNBC on Tuesday. The remark came in response to a question from the hosts of 'Squawk Box' about whether he would run for a third term, which the Constitution forbids, to which Trump replied: 'No. Probably not. I'd like to run. I have the best poll numbers I've ever had. You know why? Because people love the tariffs.' Trump was immediately fact-checked by host Joe Kernen, who pushed back that Trump has the best poll numbers among Republicans, not the general public. Trump responded that he had 'a lot of fake polls.' In late July, TIME reported that Trump's poll numbers had hit new lows, with a Gallup poll showing his approval ratings at 37% among U.S. adults. His support has dropped significantly among Independents, who cited the budget, Ukraine and foreign trade. His standing with Republicans had remained in the high 80s, though, steady throughout his second term. Trump's comments come after he has teased running for a third term throughout the first six months of his second. In some interviews, he has refused to rule out the possibility of running again, despite the 22nd Amendment of the U.S. Constitution only allowing presidents to serve two terms in office. 'A lot of people want me to do it,' Trump said in a March interview with NBC News. He added that 'there are methods which you could do it.' Many of Trump's supporters have been encouraged by the idea and have taken to chanting 'four more years' at his events. In April, the Trump Organization began selling 'Trump 2028' caps on its merchandising website, as well as t-shirts that say 'Trump 2028 (Rewrite the Rules),' In other interviews, however, Trump has denied he would seek a third term. In an April 22 interview with TIME, Trump said: 'I'd rather not discuss that now, but as you know, there are some loopholes that have been discussed that are well known. But I don't believe in loopholes.' In a May NBC interview, he added that he would rather look to other leaders in the party, including his Vice President J.D. Vance and Secretary of State Marco Rubio. The phone interview with CNBC covered Trump's tariffs, import taxes, Trump's decision to replace Fed Chair Jerome Powell, and the recent jobs report that led to Trump firing the head of the Bureau of Labor Statistics. Threats of 250% pharma tariffs Trump said that in addition to his plans to roll out tariffs on semiconductors and chips—the announcement of which he said will come 'within the next week or so'—he also wants to eventually roll out a massive tariff on pharmaceuticals to boost domestic production. 'On pharmaceuticals, we'll be putting an initially small tariff on pharmaceuticals, but in one year, one and a half years, maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country,' Trump said, threatening the highest rate thus far on the product. This news comes after a May Executive Order from Trump that directed the U.S. Department of Health and Services, led by Robert F. Kennedy Jr., to negotiate with pharmaceutical companies to reduce drug prices, which he doubled down on in late July after he sent letters to 17 drugmakers calling on them to commit to steps to lower U.S. drug prices by Sept. 29. Leaders in the pharmaceutical industry have warned, though, that these large levies will drive up drug prices. NATO leaders 'do whatever I want' Trump told CNBC hosts that the leaders of the North Atlantic Treaty Organization (NATO) 'do whatever I want.' Tensions have risen as NATO attempts to work towards a ceasefire in Russia and Ukraine, telling NBC in July that the U.S. would work through the organization to help give weapons to Ukraine. Read More: The Trump Era of Flattery Diplomacy is Here In the same interview, Trump threatened the European Union with 35% tariffs if it failed to live up to a pledge to invest some $600 billion in the U.S., and also threatened India with higher tariffs, citing their buying of Russian oil. India, he says, has 'not been a good trading partner.' Trump had criticized India's buying of Russian oil on Truth Social on Monday, claiming he would 'substantially' raise tariffs as a result. 'They're fueling the war machine. And if they're going to do that, then I'm not going to be happy,' Trump said of India in the CNBC interview Tuesday. Jobs report was 'rigged' Last week, Trump directed his Administration to fire Erika McEntarfer, head of the Bureau of Labor Statistics, following a report that showed that the U.S. added fewer jobs in July than many economists had expected, which indicated to economists that job growth stalled in the aftermath of several of Trump's controversial economic policies, including his volatile tariff policies. 'It's a highly political situation. It's totally rigged. Smart people know it. People with common sense know it,' Trump told CNBC, though host Kernan pushed back, telling Trump that this was a 'big leap' to call the report 'rigged.' 'Critics are going to say, 'Hey, he's picking a guy or a gal that's going to give him the numbers that he wants.' So it undermines confidence in the system to some extent,' Kernan told the President. Still, Trump defended his move. 'She's a very nice woman, but when they say that nobody was involved, that it wasn't political, give me a break.'
Yahoo
5 hours ago
- Yahoo
Pharmaceutical Excipients Market Size Forecasted to Surpass USD 15.43 Billion by 2034 Amid Rising Demand for Novel Drug Delivery Systems
The global pharmaceutical excipients market size is on track to exceed USD 15.43 billion by 2034, rising from USD 9.31 billion in 2025 at a CAGR of 5.75%, according to a new report by Precedence Research. Ottawa, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The worldwide pharmaceutical excipients market size was valued at USD 8.82 billion in 2024, and it is expected to attain USD 15.43 billion by 2034. The growing pharmaceutical industry and increasing demand for biologic and generic drugs drive the market growth. The market is undergoing a significant transformation, driven by the rise of biologics, demand for personalized medicine, and innovations in drug delivery systems. With the market expected to grow at a CAGR of 5.75% from 2025 to 2034, companies across the value chain are eyeing excipients as a critical component for competitive advantage. Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for Before You Buy – Get the Sample Report@ Pharmaceutical Excipients Market Key Takeaways The pharmaceutical excipients market size reached USD 8.82 billion in 2024. It is expected to exceed USD 15.43 billion by 2034. The market is growing at a CAGR of 5.75% between 2025 and 2034. The North American market size was calculated at USD 3.15 billion in 2024. North America accounted for the largest market share of 38.32% in 2024. By excipient type, the lactose-based excipients contributed the biggest market share of 41.26% in 2024. By functionality, the fillers and diluents segment generated the major market share in 2024. By functionality, the coating agents segment is expected to grow at a significant CAGR from 2025 to 2034. By excipient type, the lactose-based segment captured the highest market share 2024. By excipient type, the cellulose-based segment is projected to grow at a notable CAGR from 2025 to 2034. Pharmaceutical Excipients Market Overview What are Pharmaceutical Excipients? Pharmaceutical excipients are inactive substances formulated for drug production. They are used alongside active pharmaceutical ingredients. Pharmaceutical excipients prevent degradation and enhance the absorption of the drug. They are widely used in the production of capsules, tablets, and other drugs. They enhance the appearance, taste, texture, and compressibility of medications. Pharmaceutical excipients offer bulk to medication formulations and improve safety, efficacy, & stability of drugs. They are widely used in formulations of tablets, liquid dosage forms, capsules, creams, and ointments. 'As pharmaceutical companies strive for innovation in formulations and cost-effective manufacturing, multifunctional excipients are emerging as game-changers,' said Deepa Pandey, Principal Consultant at Precedence Research. Top Pharmaceutical Excipients Name Role Examples Diluents Provides Bulk to Formulation Microcrystalline Cellulose Calcium Phosphate Lactose Starch Binders Hold Powdered Ingredients Together Hydroxypropyl Cellulose Polyethylene Glycol Povidone Microcrystalline Cellulose Gelatin Disintegrants Break Up Tablets into Smaller Parts in Liquid Form Starch Croscarmellose Sodium Sodium Starch Glycolate Lubricants Avoid Sticking of Ingredients to Equipment Stearic Acid Magnesium Stearate Glidants Enhance Powder Mixture Flow Talc Colloidal Silicon Dioxide ➤ Get the Full Report @ Pharmaceutical Excipients Market Opportunity What is the Opportunity for the Pharmaceutical Excipients Market? The Growing Demand for Multifunctional Excipients The increasing demand for multifunctional excipients in the pharmaceutical industry for the production of pharmaceutical products creates an opportunity for the market. The growing focus on enhancing drug performance and simplifying drug formulation processes increases demand for multifunctional excipients. The increasing focus on reducing manufacturing costs and improving compliance fuels demand for multifunctional excipients. The focus on the development of sustained-release formulations and fast-dissolving tablets increases the need for multifunctional excipients. The increasing focus on personalised medicines and rapid growth in the biopharmaceutical industry increases demand for multifunctional excipients. The expansion of the healthcare industry and the growing demand for various medications are fueling demand for multifunctional excipients. The growing demand for stabilizing, binding, and disintegrating in one form fuels demand for multifunctional excipients. The growing demand for multifunctional excipients unlocks an opportunity for the growth of the pharmaceutical excipients market. For instance, the development of orally disintegrating tablets has driven demand for excipients that combine binding, taste-masking, and rapid disintegration in a single material. Limitations and Challenges in the Pharmaceutical Excipients Market Why is Pharmaceutical Excipients Development Cost High? Despite several applications of pharmaceutical excipients, the high development cost restricts the market growth. Factors like complex manufacturing processes, stringent regulatory environments, production scaling up, and extensive testing increase the development cost. The need for extensive research & development for the development of drugs increases the cost. The extensive processes like regulatory approval, research time, and testing increase the development cost. Complex manufacturing processes and the need for specialized equipment lead to higher development costs. The need for higher investment in large-scale manufacturing and lengthy development, and complex testing directly impacts the market. The regulatory approvals, like extensive evaluations and approval from regulatory bodies, increase the cost. The high development cost hampers the growth of the pharmaceutical excipients market. The timing has never been more critical. With global emphasis on rapid drug development, personalized medicine, and biologic therapies, pharmaceutical excipients are no longer passive ingredients but active enablers of innovation, efficacy, and compliance. Scope of Pharmaceutical Excipients Market Report Attributes Statistics Market Size in 2024 USD 8.82 Billion Market Size in 2025 USD 9.31 Billion Market Size by 2034 USD 15.43 Billion CAGR 2025 to 2034 5.75% Leading Region in 2024 North America (accounted for 38.32% of market share) Fastest Growing Region Europe Base Year 2024 Forecast Period 2025 to 2034 Segments Covered Functionality, Excipient Type, and Regions Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa ➡️ Become a valued research partner with us ☎ Case Study: Multifunctional Excipients Streamline Tablet Production for Generic Drug Manufacturer In 2024, a leading Indian generic pharmaceutical company adopted a multifunctional excipient combining binding, disintegration, and flow-enhancing properties in a reformulated version of its high-volume antihypertensive tablet. Key Outcomes: Reduced formulation steps by 30%, minimizing the use of multiple individual excipients. Cut production costs by 18% through improved compression and faster manufacturing cycles. Achieved 25% faster dissolution rate, improving patient compliance and therapeutic onset. Streamlined regulatory submission, thanks to excipient's prior GRAS (Generally Recognized As Safe) status and established supplier documentation. This case demonstrates the cost and performance benefits driving global demand for multifunctional excipients, particularly among high-volume, cost-sensitive drug manufacturers. Gain a competitive edge in formulation and drug delivery our pharma research team at sales@ or book a 1:1 session to unlock segment-specific insights. Pharmaceutical Excipients Market Key Regional Insights How Did North America Dominate Pharmaceutical Excipients Market in 2024? North America dominated the pharmaceutical excipients market in 2024, owing to the strong presence of a well-developed and advanced pharmaceutical industry in the region increases the demand for pharmaceutical excipients for the production of drugs. The extensive investment in research & development of pharmaceuticals helps in the market growth. The growing demand for generic drugs increases demand for pharmaceutical excipients. The increasing development of advanced drug formulations and drug delivery systems increases demand for pharmaceutical excipients. The stringent regulations for the development of excipients help the market growth. The increasing demand for personalised medicines and focus on biologics drive the market growth. U.S. Pharmaceutical Excipients Market Size and Forecast 2025 to 2034 How big is the U.S. Pharmaceutical Excipients Market? According to Precedence Research, the U.S. pharmaceutical excipients market size reached USD 2.90 billion in 2024 and is expected to grow from USD 3.08 billion in 2025 to USD 5.32 billion by 2034, registering a CAGR of 6.26% from 2025 to 2034. Key Market Drivers and Insights Strong generics penetration in the U.S. elevates demand for excipients, especially in oral dosage forms like tablets and capsules. Advanced formulations, including controlled-release and biopharma delivery systems, are boosting growth in high-performance excipients and coating agents. Regulatory clarity and infrastructure investment maintain the region's dominance, with substantial R&D in U.S.-based excipient solutions. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ How is Asia Pacific the Fastest Growing in the Pharmaceutical Excipients Market? Asia Pacific is experiencing the fastest growth in the market during the forecast period, owing to the growing healthcare spending and rising demand for various pharmaceutical products that increase the demand for pharmaceutical excipients. The increasing expansion of generic drugs helps the market growth. The focus on personalised medicines and advancement in drug delivery systems fuels demand for pharmaceutical excipients. The strong government support for the pharmaceutical industry and growing investment in R&D help the market growth. The rise in biosimilars & biologics and the expansion of nutraceuticals support the market growth. Top Three Asian Exporters of Pharmaceutical Excipients: Countries Export Leading Suppliers Japan 356 Shipments SHIN ETSU CHEMICAL CO, LTD China 200 Shipments WELLSTARS INTERNATIONAL CO, LTD India 106 Shipments Amtec Health Care Pvt Ltd (Source: Pharmaceutical Excipients Market Segmentation Analysis: Functionality Analysis Why did Fillers and Diluents Segment Dominate the Pharmaceutical Excipients Market? The fillers and diluents segment dominated the pharmaceutical excipients market in 2024. The easy availability of different forms and grades of fillers and diluents helps the market growth. The need for achieving the desired weight & size of capsules & tablets increases demand for fillers & diluents. They contribute to tablet content uniformity and improve the flow properties of tablet formulations. Fillers & diluents enhance production efficiency, tablet compression, and flow properties. The growing demand for different starches, lactose, and microcrystalline fillers & diluents drives the market growth. The coating agent segment is significantly growing in the market during the forecast period. The growing focus on improving patient experience increases demand for coatings to cover up the unpleasant odor and taste of medications. The increasing demand for protecting active ingredients in pharmaceutical production fuels demand for coating agents. The growing prevalence of chronic diseases increases demand for coated medications. Coating agents enhance drug delivery and control drug release in the body. The rising adoption of oral solid medications like capsules & tablets supports the market growth. Excipient Type Analysis How Lactose-Based Segment Held the Largest Share of the Pharmaceutical Excipients Market? The lactose-based segment held the largest revenue share of the pharmaceutical excipients market in 2024 due to growing demand for binder, flow agent, filler, and diluent in various pharmaceutical applications that increases demand for lactose-based excipients. They are available in various forms like spray-dried, anhydrous, & monohydrate and are compatible with various APIs. Lactose-based excipients have good flowability, low hygroscopicity, excellent compressibility, and good solubility. They are easily available and cost-effective for pharmaceutical production. The increasing demand across applications like lyophilization, solid dosage forms, and inhalation products drives the market growth. The cellulose-based segment is significantly growing in the market during the forecast period. The growing demand for cellulose-based excipients across various pharmaceutical applications like controlled-release formulations, tablet binding, and disintegration helps the market growth. The increasing demand for generic drugs fuels demand for cellulose-based excipients. They are derived from a plant source and improve the bioavailability of less soluble drugs. The growing development of patient-friendly drug delivery systems and orally dissolving tablets supports the market growth. ✚ Related Topics You May Find Useful ➤ ➡️Pharmaceutical Manufacturing Market: Advancing efficiency through automation, AI, and global capacity expansion ➡️Pharmaceutical Chemicals Market: Meeting rising API demand with stringent quality and compliance standards ➡️Nutraceutical Excipients Market: Enhancing bioavailability and stability with clean-label formulations ➡️High-Potency API Market: Enabling targeted therapies for oncology and rare diseases ➡️Biotech Ingredients Market: Supporting biologics growth with innovative, high-purity ingredients ➡️Pharmaceutical Intermediates Market: Accelerating complex drug development via outsourcing and specialty production ➡️Pharma Contract Manufacturing & Research Market: Strengthening drug pipelines with advanced outsourcing solutions Pharmaceutical Excipients Market Top Companies The pharmaceutical excipients market is dominated by key players who collectively command the largest market share and significantly influence industry trends. Ashland Global Holdings BASF SE DuPont Roquette Feres Evonik Industries AG Associated British Foods Archer Daniels Midland Company Lubrizol Corporation Croda International Kerry Group Recent Developments In November 2024, Clariant launched new high-performing excipients for effective medicines. The excipients are available for various applications like parenteral formulations and sensitive active pharmaceutical industries. The range offers high-quality, tailored, reliable, and cost-effective solutions for the healthcare sector in India. (Source: In January 2025, GELITA launched Endotoxin Controlled Excipients for pharmaceutical and bioscience applications. The product range includes MEDELLAPRO and VACCIPRO, that used in applications like 3D bioprinting, vaccine stabilisation, and medical devices. The excipients ensure patient safety and well-being. (Source: In December 2023, Roquette launched three new excipient grades, MICROCEL 113 SD, LYCATAB CT-LM, and MICROCEL 103 SD. The new excipients support the development of drugs and focus on improving the experience of producers & patients. (Source: In May 2025, Pharcos Specialty Ltd launched India's first homegrown hydroxypropyl methylcellulose excipients for the pharmaceutical industry. The excipients are used in the coating of tablets & pellets, stabilization of suspensions, thickening agent in pharmaceutical formulations, controlled-release matrix system, wet granulation & binder system, manufacturing vegetarian tablets, and frozen food & food dietary. (Source: Pharmaceutical Excipients Market Segments Covered in the Report By Functionality Fillers and Diluents Suspending and Viscosity Agents Coating Agents Binders Disintegrants Colorants Lubricants and Glidants Preservatives Emulsifying Agents Flavoring Agents and Sweeteners Other Functionalities By Excipient Type Lactose-based Excipients α-lactose monohydrate Anhydrous α-lactose Anhydrous β-lactose Amorphous Lactose Cellulose-based Microcrystalline Cellulose (MCC) Cellulose Ethers Others Starches Carboxymethylcellulose Sodium (CCS) Sodium Starch Glycolate (SSG) Fine Chemicals Mannitol Biopharma Excipients Others By Region North America U.S. Canada Europe Germany UK France Italy Spain Sweden Denmark Norway Asia Pacific China Japan India South Korea Thailand Latin America Brazil Mexico Argentina Middle East & Africa South Africa UAE Saudi Arabia Kuwait Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as Immediate Delivery Available | Buy This Premium Research Report@ You can place an order or ask any questions, please feel free to contact at sales@ | +1 804 441 9344 Stay Ahead with Precedence Research Subscriptions Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve. Browse Our Subscription Plans@ About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. Web: Our Trusted Data Partners: Towards Healthcare | Towards Packaging | Towards Automotive | Towards Chem and Materials | Towards FnB | Towards Consumer Goods | Statifacts | Towards EV Solutions | Towards Dental | Nova One Advisor | Market Stats Insight Get Recent News: For the Latest Update Follow Us: LinkedIn | Facebook | TwitterError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
18 hours ago
- Business Upturn
IEX hits record electricity trade volume of 12,664 MU, up 25.5% YoY in July 2025
Indian Energy Exchange (IEX), the country's leading electricity trading platform, clocked its highest-ever monthly electricity trade volume in July 2025. The exchange reported a total traded volume of 12,664 million units (MU), including the Term-Ahead and Real-Time Ancillary Services (TRAS), marking a robust 25.5% year-on-year growth. This surge in volumes came even as India's power consumption touched 153.6 billion units (BUs) during the month, as per government data—up 2.6% YoY. Interestingly, despite the higher demand, market clearing prices fell sharply on the back of stronger supply-side liquidity. The Day-Ahead Market (DAM) settled at an average Rs 4.18 per unit, down 16% YoY, while Real-Time Market (RTM) prices dropped 23% YoY to Rs 3.83 per unit. These lower prices provided cost-effective opportunities for Discoms as well as commercial and industrial consumers to meet their power needs through exchange-based procurement. Day-Ahead, Term-Ahead & Real-Time Market Performance The DAM, including HPDAM, recorded 5,510 MU in July 2025, up 9% from July 2024. The RTM achieved its highest-ever monthly volume of 5,109 MU, a sharp 53% YoY rise. The Term-Ahead Market (TAM), including various short-term contracts, traded 917 MU, up 28% YoY. Green Market Trends: G-DAM & G-TAM The Green Market—comprising the Green Day-Ahead Market (G-DAM) and Green Term-Ahead Market (G-TAM)—continued its steady growth. In July 2025, the green segment recorded 1,025 MU, compared to 990 MU in July 2024, posting a 4% YoY increase. The weighted average price in G-DAM stood at Rs 3.91/unit. Renewable Energy Certificate (REC) Market Update In the two trading sessions held on July 9 and July 30, IEX facilitated trading of 16.26 lakh RECs at a clearing price of Rs 360 per REC. However, the REC trade volume declined by 48% YoY. The next REC trading sessions are scheduled for August 13 and August 27, 2025. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
